SEC Form 4 · accession 0001571049-16-015673
Cyclacel Pharmaceuticals, Inc. · CYCC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nicholas G Bacopoulos
Director
Period of report
May 26, 2016
Accepted (ET)
May 31, 2016 · 4:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001130166
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OptionF1 | $0.429 | May 26, 2016 | A | 15,000 | A | May 26, 2017 | May 26, 2026 | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F1These options were granted to Dr. Bacopoulos for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc.